Multicenter phase 2 trial of hypofractionated proton beam therapy for unresectable primary liver tumors: long-term outcomes and biomarker correlates

A multicenter phase 2 trial evaluated proton hypofractionated ablative radiotherapy (HART) for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). Long-term outcomes and biomarker correlates have now been published. A total of 92 patients with localized unresectable HCC or ICC with Child-Pugh class A/B liver function received HART (up to 67.5 GyE in 15 fractions). Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Plasma samples were collected at baseline, day 1, 8, and 15, and 1 month after treatment. Among evaluable patients (44 HCC and 39 ICC), the median OS was 29.2 months (HCC) and 20.8 months (ICC), with 5-year OS rates of 25.9% and 12.3%, respectively. The median PFS was 13.8 months (HCC) and 8.4 months (ICC). In-field local failure occurred in 2 HCC patients (4.5%) and 7 ICC patients (17.9%), whereas out-of-field intrahepatic/distant progression remained the predominant pattern of failure. No grade ≥ 3 treatment-related toxicities were observed. Exploratory plasma profiling identified distinct biological signatures associated with progression; HCC was characterized by markers of hypoxia, inflammation, vascular remodeling, stromal activation, and hepatic regeneration, whereas association in ICC predominantly involved signatures of hypoxia and vascular remodeling. The authors conclude that HART provided durable long-term in-field local control with minimal toxicity, but disease progression remains predominantly out-of-field intrahepatic/distant.